{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "45c59f70-8659-4f3f-b962-fda05a7785b7",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "1395079c-3f87-460c-89c9-e1517276d321",
          "code": {
            "id": "abf248f7-b69d-424b-8a36-13b44489c333",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "144f7b29-18a5-40b0-b150-b05e6f6ebbb9",
            "type": {
              "id": "d0c1527a-e486-4cf2-be01-5c4dc1e7b4fa",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment 1 to the protocol",
        "effectiveDate": "2014-06-12",
        "previousVersion": "Original",
        "newVersion": "1"
      },
      {
        "id": "amend_2",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "f49282bf-a765-4ad5-a4bb-d21df242e688",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "a3735742-7746-424b-8d97-a67600606acd",
          "code": {
            "id": "0b6d5d35-76fa-47d5-8cbc-a4b5241d6602",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "fff8ed39-a0c9-45e7-b138-76fc2aba0081",
            "type": {
              "id": "9b633d80-8609-40d9-827f-59c525b75fba",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment 2 to the protocol",
        "effectiveDate": "2015-02-11",
        "previousVersion": "1",
        "newVersion": "2"
      },
      {
        "id": "amend_3",
        "number": "3",
        "name": "Amendment 3",
        "scope": {
          "id": "86a07e68-583f-4e42-9dce-ee4b8e2e1638",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "1b299594-1c51-4b60-84c9-6d4e17a0c29a",
          "code": {
            "id": "9f696331-e7a9-481e-927c-51a00d66308d",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "65a97e6e-0dc3-4967-9dd0-eb056c0a8cc2",
            "type": {
              "id": "0173a0a1-4f3f-4835-9fbc-6701431c0be7",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment 3 to the protocol",
        "effectiveDate": "2016-06-17",
        "previousVersion": "2",
        "newVersion": "3"
      },
      {
        "id": "amend_4",
        "number": "4",
        "name": "Amendment 4",
        "scope": {
          "id": "d3c27cf6-048f-4bd7-932b-5c16d05f3e1f",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "5d1d7f84-4396-47c2-8d41-b8aff81d8349",
          "code": {
            "id": "b3e9c805-6c57-4c4f-bfc3-cb5d5e82edd0",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "563e373e-64b6-4425-a9f1-77b0e5d55213",
            "type": {
              "id": "b06a8180-b30f-4f94-b7dd-5fe1a2c921bd",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The purpose of this amendment is to add benefits and risks evaluation information and updated study procedures in the context of the ongoing COVID-19 pandemic; introduce the option of off-site phone visits every other cycle for subjects who have been receiving single-agent veliparib/placebo at a stable dose; remove references to Blinded/Unblinded TA MD and study teams as the sponsor was unblinded at the time of primary analysis; allow removal of requirements for central laboratory and central radiology review; update tumor assessment schedule from every 9 weeks to allow every 12 weeks; update IDMC review language; update guidelines on when chemotherapy can begin based on hematologic blood counts; add language on reporting of myelodysplastic syndrome, acute myeloid leukemia, or secondary primary malignancy; and modify the Table of Study Procedures for Post Treatment Phase.",
        "effectiveDate": "2020-07-23",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2",
          "ar_4_3",
          "ar_4_4",
          "ar_4_5"
        ],
        "previousVersion": "3",
        "newVersion": "4"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_4_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_3",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_4",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_5",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "Australia",
        "instanceType": "Country",
        "code": "AU"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 4,
      "countryCount": 2,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2"
      ],
      "regions": [
        "North America",
        "Australia",
        "Northern Europe",
        "Western Europe",
        "Eastern Europe",
        "European Union"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "1",
        "effectiveDate": "2014-06-12",
        "summary": null,
        "previousVersion": "Original",
        "newVersion": "1",
        "reasons": []
      },
      {
        "number": "2",
        "effectiveDate": "2015-02-11",
        "summary": null,
        "previousVersion": "1",
        "newVersion": "2",
        "reasons": []
      },
      {
        "number": "3",
        "effectiveDate": "2016-06-17",
        "summary": null,
        "previousVersion": "2",
        "newVersion": "3",
        "reasons": []
      },
      {
        "number": "4",
        "effectiveDate": "2020-07-23",
        "summary": "The purpose of this amendment is to add benefits and risks evaluation information and updated study procedures in the context of the ongoing COVID-19 pandemic; introduce the option of off-site phone visits every other cycle for subjects who have been receiving single-agent veliparib/placebo at a stable dose; remove references to Blinded/Unblinded TA MD and study teams as the sponsor was unblinded at the time of primary analysis; allow removal of requirements for central laboratory and central radiology review; update tumor assessment schedule from every 9 weeks to allow every 12 weeks; update IDMC review language; update guidelines on when chemotherapy can begin based on hematologic blood counts; add language on reporting of myelodysplastic syndrome, acute myeloid leukemia, or secondary primary malignancy; and modify the Table of Study Procedures for Post Treatment Phase.",
        "previousVersion": "3",
        "newVersion": "4",
        "reasons": [
          "Safety",
          "Operational",
          "Regulatory",
          "Scientific",
          "Administrative"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "Australia",
          "code": "AU"
        }
      ],
      "regions": [
        "North America",
        "Australia",
        "Northern Europe",
        "Western Europe",
        "Eastern Europe",
        "European Union"
      ],
      "plannedSites": 200
    },
    "sites": []
  }
}